InvestorsHub Logo
Followers 4
Posts 585
Boards Moderated 0
Alias Born 03/12/2010

Re: confirm post# 27374

Sunday, 12/09/2018 9:32:18 PM

Sunday, December 09, 2018 9:32:18 PM

Post# of 36437
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.

(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!



Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)